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Abstract: Somatotropin (growth hormone, GH) of recombinant DNA origin has provided a 
readily available and safe drug that has greatly improved management of children and ado-
lescents with GH deﬁ  ciency (GHD) and other disorders of growth. In the US and Europe, 
regulatory agencies have given approval for the use of GH in children and adults who meet 
speciﬁ  c criteria. However, clinical and ethical controversies remain regarding the diagnosis 
of GHD, dosing of GH, duration of therapy and expected outcomes. Areas which also require 
consensus include management of pubertal patients, transitioning pediatric patients to adult-
hood, management of children with idiopathic short stature and the role of recombinant IGF-1 
in treatment. Additionally, studies have demonstrated anabolic beneﬁ  ts of GH in children who 
have inﬂ  ammatory-based underlying disease and efﬁ  cacy of GH in overcoming growth delays 
in people treated chronically with corticosteroids. These areas are open for possible new uses 
of this drug. This review summarizes current indications for GH use in children and discusses 
areas of clinical debate and potential anabolic uses in chronic illness.
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Introduction
Somatotropin (growth hormone, GH) of recombinant DNA origin has been com-
mercially available since 1985. It replaced human pituitary-derived GH, which was 
withdrawn for safety concerns. Regulatory agencies in Europe and North America have 
authorized its use for certain conditions based on data indicating safety and efﬁ  cacy. 
The current approved conditions in the US include: growth hormone deﬁ  ciency (GHD), 
idiopathic short stature (ISS), Turner syndrome (TS), Prader-Willi syndrome (PWS), 
chronic renal insufﬁ  ciency (CRI), small for gestational age (SGA) and Noonan’s 
Syndrome. Despite authorization for use, controversy remains. Concerns include cost 
versus beneﬁ  t, and in some cases, safety. GH has known anabolic effects and several 
chronic illnesses have been studied by clinical trials to determine potential beneﬁ  ts of 
GH. Although several good summaries exist, this review is intended to extend these 
discussions. We will summarize beneﬁ  ts and controversies for approved GH indications 
in children, discuss current controversies in safety and efﬁ  cacy and discuss potential 
anabolic use for chronic illness.
Growth hormone deﬁ  ciency
Approximately 1 in 3500 children in the US are diagnosed with growth hormone deﬁ  -
ciency (GHD) (Lindsay et al 1994). Only 20% of these children have organic GHD. 
Organic causes include central nervous system tumors, radiation, infection, and trau-
matic brain injury. Approximately 80% of children do not have a readily identiﬁ  able 
cause of GHD. These patients are classiﬁ  ed as having idiopathic GHD.Biologics: Targets & Therapy 2008:2(4) 656
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In many US states, current insurance requirements 
require the use of secretagogue testing to diagnose GHD 
(Levy and Connelly 2003). However, a survey of pediatric 
endocrinologists in North America found that 95% of endo-
crinologists do not believe secretagogue testing is the best 
method of identifying who should be offered treatment with 
GH (Hardin et al 2007). This is in part due to the recogni-
tion that arbitrary cut-off values exist for deﬁ  ning GHD, 
the lack of reproducibility for test results and the fact that 
some children with remarkably abnormal growth velocity 
will have “normal” results to secretagogue testing. There 
may, however, be a resurgence of enthusiasm for stimulation 
testing due to the recent approval for recombinant IGF-1 
to treat IGF-1 deﬁ  cient children. Secretagogue testing or 
IGF-1 stimulation testing are needed to distinguish IGF-1 
deﬁ  ciency from GH deﬁ  ciency. The consensus of opinion 
from pediatric endocrinologist’s survey (Hardin et al 2007), 
the Growth Hormone Research Society (2000) and from the 
North American Lawson Wilkins Pediatric Endocrine Society 
(Wilson et al 2003) indicate that a diagnosis of GHD requires 
integration of auxologic criteria, medical history, laboratory 
tests, and radiologic assessments. Referral to an endocrinolo-
gist should be made for children with height 3rd percentile, 
those with low growth velocity and those who demonstrate 
signiﬁ  cant disparity between projected height and expected 
mid-parental height (Juul et al 1994).
Studies indicate that ﬁ  nal adult height is increased with 
early therapy, thus the earlier the diagnosis, the better the 
prognosis for height. Furthermore studies indicate greater 
efficacy with larger GH doses, and continuous therapy 
(Blethen et al 1996; MacGillivray et al 1996, 1998). Thus it 
is important that primary care providers give early referral 
for evaluation of children with short stature, children with 
declining height percentiles, and for children not growing in 
concordance with their predicted adult height.
The duration of GH therapy is controversial. For many 
years, GH was given until epiphyseal fusion. New data 
suggests GH has important beneﬁ  ts for bone mineraliza-
tion, lean mass (Saggese et al 1996; Underwood et al 2003; 
Boguszewski et al 2005) and improves cardiac risk factors, 
such as decreasing visceral adipose tissue and improving lipid 
proﬁ  le (Colao et al 2002; Lanes et al 2003; Underwood et al 
2003). These beneﬁ  ts have led to approval for GH treatment 
of adults (in lower doses) and suggest GH treatment should 
be life-long. Re-evaluation to determine if GH deﬁ  ciency 
is persistent is indicated. Despite the recent development 
of guidelines for managing transitioning patients (Clayton 
et al 2005), differences in opinion remain regarding how and 
when this reassessment should be performed, the optimal 
GH dose in the transition period, and the respective roles of 
adult and pediatric providers in managing the endocrine care 
of transitioning patients.
Optimal dosing of GH during puberty is also contro-
versial. In normal children, pubertal sex-steroid production 
independently stimulates growth and increases GH secretion, 
resulting in the pubertal growth spurt. Studies suggest that 
GHD patients may achieve greater pubertal growth if treated 
with GH doses higher than those used in prepubertal children 
(Codner et al 1997; Mauras et al 2000; Saenger 2003). How-
ever, controversy exists regarding the beneﬁ  t in height versus 
the additional cost of therapy (Allen and Fost 2004). IGF-1 
levels are speciﬁ  c for pubertal stage and gender, and good 
evidence suggests that monitoring IGF-I levels is useful in 
determining an optimal and safe GH dose (Park and Cohen 
2004). At no time is this likely more important than during 
puberty. It seems logical that GHD children should have GH 
dosed according to maintenance of IGF-1 levels speciﬁ  c for 
pubertal stage and gender so that growth is maximized.
Other FDA-approved indications
Idiopathic short stature (ISS)
Idiopathic short stature (ISS) is deﬁ  ned by a height 2.25 
or more standard deviations below the mean (or less than 
the 1.2 percentile) for age and gender without evidence of 
underlying disease or GHD (Rekers-Mombarg et al 1999). 
This deﬁ  nition applies to approximately 400,000 children in 
the US and includes a diverse group of patients. In the US, 
the FDA approved GH for ISS in 2003. Similar approval 
does not exist in Europe. The degree of height improvement 
resulting from GH treatment of ISS children varies depend-
ing on the research study (Hintz et al 1999; Finkelstein et al 
2002; Leschek et al 2004; Kemp et al 2005). Use of GH for 
the ISS indication remains controversial, in part due to the 
variability in reported height improvement, but also due to 
poorly deﬁ  ned measures of therapeutic success (eg, improved 
psychosocial adjustment), and debate about whether the goal 
of treatment should be simply a “normal” height or “maxi-
mum” height (Allen and Fost 2004). There is little consensus 
among endocrinologists about GH use in children with ISS 
and unfortunately it has led to dissention in the Endocrine 
community (Hardin et al 2007). Further complicating mat-
ters is the increased public awareness of the ISS indication 
resulting in requests for therapy with GH. Evaluation by a 
specialist is recommended for children with heights at the 3rd 
percentile or less, and poor growth velocity. Early referral 
(before puberty) will provide time for a greater height beneﬁ  t Biologics: Targets & Therapy 2008:2(4) 657
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should treatment be needed. The endocrine community needs 
to explore the polarization on this topic and seek tolerance 
for diversity of opinion.
Turner syndrome (TS)
Girls with TS have an abnormal or missing X chromosome, 
resulting in short stature and ovarian failure (Saggese et al 
1996). TS occurs in 1 in 2,500 live female births, making 
it a common cause of short stature in girls. Variability in 
phenotypic features often contributes to a delay in diagnosis; 
therefore, karyotyping is recommended for any young female 
with unexplained short stature (height below 5th percentile), 
delayed puberty, or any clinical features of TS (Savendahl 
and Davenport 2000). GH therapy increases the growth 
rate and ﬁ  nal adult height of girls with TS (Sas et al 1999; 
Chernausek et al 2000). Studies indicate the improvement in 
growth is related to the dose and duration of therapy before 
the initiation of estrogen replacement therapy (Chernausek 
et al 2000). Some studies suggest addition of oxandrolone 
adds to ﬁ  nal height (Rosenfeld et al 1998; Sas et al 1999; 
Chernausek et al 2000; Reiter et al 2001). The dose of GH 
recommended for treatment of TS is 0.375 mg/kg/week 
(Rosenfeld et al 1998). A recent study (Davenport et al 2007) 
clearly suggests that GH therapy before the age of ﬁ  ve is 
safe and improves ﬁ  nal height. Early diagnosis promotes 
coordination of management strategies to prevent TS-related 
morbidities (eg, cardiovascular and otologic) and may also 
increase adult height by allowing a longer duration of GH 
therapy before initiation of estrogen replacement (Reiter 
et al 2001).
Chronic renal insufﬁ  ciency (CRI)
Short stature is common in children with CRI. Several 
reasons contribute to the pathogenesis including metabolic 
acidosis, water-electrolyte disturbances, protein-calorie mal-
nutrition, renal osteodystrophy, and corticosteroid treatment 
which create resistance to the action of GH (Kuizon and 
Salusky 1999; Roelfsema and Clark 2001). Abnormalities in 
the GH-IGF-I axis may also contribute (Roelfsema and Clark 
2001). Most patients with renal disease have high levels of 
GH secondary to decreased renal clearance; however, they 
also have decreased numbers of GH receptors, increased 
production of IGF-binding proteins and a reduction in bio-
available IGF-I. Despite these metabolic alterations, studies 
have demonstrated that GH therapy signiﬁ  cantly increases 
linear growth (Fine et al 1994a; Hokken-Koelega et al 2000; 
Haffner et al 2000), bone mineral density (Van Dyck et al 
2001), body weight, and lean mass in CRI (Fine et al 1994b). 
Moreover, GH does not accelerate the progression of renal 
insufﬁ  ciency or hasten the need for dialysis (Tonshoff et al 
1992). Although CRI is an FDA-approved indication, GH 
use for these patients has been limited (<10% of children 
registered in the North American Pediatric Renal Transplant 
Cooperative Study) (Study 2005). One possible reason is the 
lack of adult height data since only recent trials have included 
adult height as an end point (Fine et al 1994b). Furthermore, 
height may be perceived as a less serious concern in the 
setting of other complex medical problems experienced by 
children with CRI. Nevertheless, growth failure remains a 
signiﬁ  cant clinical problem in these children, and treatment 
with GH should be started as soon as possible. The continua-
tion of GH after renal transplantation is still a matter of con-
troversy and long-term, post-transplant studies are needed.
Prader-Willi syndrome (PWS)
In the US the FDA approved GH for treatment of PWS in 
2000. PWS is a genetic disorder caused by deletion or lack of 
expression of a portion of the paternally derived chromosome 
15 and occurs in approximately 1 in 25,000 births. Although 
diagnostic criteria are available (Gunay-Aygun et al 2001), 
the non-speciﬁ  c features of PWS in infancy often contribute 
to a delayed diagnosis. Clinical ﬁ  ndings include a decline in 
linear growth, as well as hypotonia, hyperphagia, obesity, 
hypogonadism, sleep disorders, and behavioral abnormali-
ties (Goldstone 2004). Hypothalamic dysfunction results 
in GHD. The efﬁ  cacy of GH therapy in improving linear 
growth, physical strength and agility, and body composition 
in children with PWS is well documented (Carrel et al 1999, 
2001, 2002). A recent study (Carrel et al 2004) demonstrates 
safety and efﬁ  cacy in infants. Studies also demonstrate posi-
tive changes in lipid proﬁ  le and increased muscle force (Haqq 
et al 2003). A recent dosing recommendation proposes use of 
0.24 mg/kg/week based on ideal body weight (Lindgren and 
Ritzen 1999). Sudden death has been reported in 17 children 
with PWS who were treated with GH (Van Vliet et al 2004). 
These children had underlying early presentation of morbid 
obesity (BMI 31–42 kg/m2), respiratory, and/or possible 
sleep disorders, and in general were very young (Eiholzer 
2005). It remains possible, but not certain, that GH therapy 
might have contributed to these deaths (Van Vliet et al 2004; 
Eiholzer 2005). If GH were a contributing factor, the leading 
hypothesis as to the cause is that of airway obstruction from 
soft tissue hypertrophy; however, to date there is no published 
evidence that such hypertrophy contributed to these deaths. 
Most endocrinologists now recommend sleep studies and 
correction of underlying airway obstruction prior to initiating Biologics: Targets & Therapy 2008:2(4) 658
Hardin
GH treatment (Allen and Carrel 2004). Many clinicians 
believe that the beneﬁ  ts of GH treatment outweigh the risks 
in children with PWS; however, there is still debate.
Small for gestational age (SGA)
Approximately 90,000 infants are born SGA in the US 
each year (Lee et al 2003). Most exhibit postnatal growth 
acceleration and have adequate catch-up growth by age 2, 
with most catch up growth occurring in the ﬁ  rst 6 months 
(Kelnar 2003a). It is important to know that in pre-term 
infants, growth acceleration can be delayed up to age 5 years 
(Boonstra et al 2003). Despite adequate growth in most 
patients, in approximately 10% of patients, the pattern of 
growth continues to be abnormal with height  –2.5 SDS 
(Davenport 2005).
GH was approved for children born SGA in 2001 in the 
US and in Europe in 2003. The reported beneﬁ  ts of GH in 
increasing ﬁ  nal adult height and bone mineral density in 
children born SGA support evaluation for possible treat-
ment (Arends et al 2003; Van Pareren et al 2003; Dahlgren 
and Wikland 2005). Endocrinologists should rule out other 
potential causes for poor growth before treating, but clearly 
treatment should be offered when other causes have been 
excluded. Aspects of treatment needing on-going study 
include determining the optimal dose and duration of treat-
ment. Recent studies (Hokken-Koelega et al 1995; Drake 
et al 2001) suggest that children who initiate GH during mid 
to late childhood, and those with growth retardation below 3 
SDS, may need higher doses of GH than traditional dosing. 
Many children born SGA have additional medical problems 
and have documented risk for metabolic disorders including 
hypertension, hyperlipidemia, insulin resistance, and cardio-
vascular disease (later life) (Harris et al 2004). Monitoring 
for these problems is important for the endocrinologist and 
the primary care physician.
Short bowel syndrome (SBS)
GH has been approved for SBS therapy in the US for patients 
receiving “specialized nutritional support” including high-
carbohydrate, low-fat diet, enteral or parenteral nutrition and 
patients receiving certain elemental diets (Zorbtive). The 
approval was not limited to a speciﬁ  c age, yet no speciﬁ  c 
pediatric trials were presented to the FDA. The adult stud-
ies used to garner approval documented decreased need for 
parenteral nutrition when GH was given for 6 weeks. Stud-
ies are needed to determine optimal dose and duration of 
therapy for pediatric patients. The current recommended dose 
is 0.1–0.8 mg/kg daily (Zorbtive). In adults with SBS, the 
administration of  GH has promoted signiﬁ  cant improvement 
in nutrient absorption, body weight, and lean body mass 
(Seguy et al 2003). Studies are needed in children.
Noonan’s syndrome
Noonan’s syndrome, an autosomal dominant condition occur-
ring in 1:1000–1:2500 live births, is the most recent FDA 
approved indication for GH therapy. The syndrome is charac-
terized by some clinical features similar to Turner syndrome 
and include: short stature, pulmonary valvular stenosis, facial 
dysmorphy and hypertelorism, thoracic cage excavation, 
paddle neck, moderate mental retardation, deafness, hypo-
gonadism, cryptorchidism, and coagulation abnormalities 
(Asokan et al 2007). There appears to be GH/IGF-1 axis 
abnormalities. Studies have indicated that GH improves height 
in these children; however, most trials have been small (Kirk 
et al 2001; Kelnar 2003b). One group of Noonan syndrome 
patients, those with a gene mutation in PTPN 11, have lower 
basal height (Ferreira et al 2005). This gene is responsible 
for GH/IGF-1 signal transduction in cells and some small 
reports suggest Noonan’s patients with this mutation may 
have less response to GH (Kirk et al 2001). It is possible the 
recombinant IGF-1 therapy may provide better growth than 
GH in this patient subset; studies are needed.
Off-label clinical applications 
that have shown potential beneﬁ  t
Chronic illness in children is often associated with poor 
growth which may be related to the underlying disorder, to 
poor nutrition, or to the administration of growth-inhibiting 
drug therapies such as glucocorticoids. In all chronic ill-
nesses, poor growth has been linked to less favorable clinical 
outcomes. Thus several chronic conditions have sparked 
investigation of GH as an anabolic agent.
Although FDA approval of GH therapy for adults with 
AIDS wasting has been obtained, use in HIV-infected and 
AIDS wasted children is considered off-label. Children 
infected with HIV frequently exhibit decreased growth 
velocity compared to healthy age-matched children 
(Saavedra et al 1995). This growth decline has been shown 
to correlate signiﬁ  cantly with viral burden (Johann-Liang 
et al 2000, Arpadi et al 2000). GH therapy has been shown 
to increase height and weight in children infected with HIV 
but has not been associated with an increase in viral burden 
(Hardin et al 2005b).
Multiple studies (Alemzadeh et al 1998; Hardin et al 
1998, 2001, 2005a), including two large multi-center trials 
(Hardin et al 2006; Schnabel et al 2007), have demonstrated Biologics: Targets & Therapy 2008:2(4) 659
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good improvement in linear growth, body weight, lean mass, 
and bone mineral content and reduces hospital admissions 
in children with cystic ﬁ  brosis.
In Europe, but thus far not the US, GH has been approved 
for use to reverse steroid-mediated growth failure for patients 
with juvenile inﬂ  ammatory arthritis. Not only has GH been 
shown to decrease loss of growth velocity in these children, 
but to also promote accretion of bone and muscle mass 
(Bechtold et al 2005). Studies in children with poor growth 
resulting from treatment with glucocorticoids for any rea-
son demonstrated, on average, a doubling of growth rate in 
response to rhGH (Allen et al 1998).
Finally, GH has been shown to signiﬁ  cantly increase 
fat-free mass, bone mineral accretion, weight gain, and 
linear growth without adversely affecting disease activity or 
carbohydrate tolerance in children who have inﬂ  ammatory 
bowel disease (IBD) (Mauras et al 2002). Although beneﬁ  cial 
effects of GH may be important to individuals with these con-
ditions, it is uncertain whether approval for these indications 
is forthcoming; therefore endocrinologists need to determine 
the appropriateness of GH therapy on an individual-patient 
basis and prescribe the drug “off-label”.
Safety
Prior to recombinant GH, Creutzfeldt-Jakob disease occurred 
in some patients treated with contaminated pituitary-derived 
GH (Hintz 1995). Once recombinant GH was produced, 
patient registries were established to allow long-term safety 
monitoring in a large number of patients. Data from the 
largest registries include the Kabi International Growth Study 
(KIGS) including children from the US and Europe, and the 
National Cooperative Growth Study (NCGS), which includes 
only children from the US. Both registries indicate that long-
term use of GH is not associated with an increased risk of 
primary leukemia or other malignancies in patients who have 
not had pre-existing blood-born or solid tumors (Blethen 
et al 1996; Maneatis et al 2000). They also demonstrate that 
although GH can reduce insulin sensitivity, the incidence 
of diabetes mellitus in children treated with GH is similar 
to that expected in the general population (Bell et al 2005). 
Other problems have been rarely reported and include: benign 
intracranial hypertension, slipped capital femoral epiphysis, 
scoliosis, pancreatitis, and adrenal insufﬁ  ciency (Mills et al 
2004). In general, these events represent heightened sensitiv-
ity to the physiological effects of GH (eg, sodium and water 
retention, growth rate acceleration) or the unmasking of 
underlying conditions of treated patients. Endocrinologists 
must carefully monitor pituitary hormone levels and clinical 
status in patients prior to and during GH treatment (Growth 
Hormone Research Society 2001). However, there is clear 
consensus among endocrinologists that the beneﬁ  ts of GH 
outweigh its risks (Hardin et al 2007).
Cost and controversy
Eligibility for treatment with GH is one of the most controver-
sial areas in pediatric endocrinology. Members of the Lawson 
Wilkins Pediatric Endocrinology Society cited the cost as one 
major factor limiting their prescribing of the drug (Hardin 
et al 2007). Prescribing choices are increasingly limited by 
hospital or insurance formulary decisions. At the present 
time, all pharmaceutical companies that produce GH charge 
similar prices for the drug and injection devices. Therefore 
careful investigation regarding dose and duration of  therapy 
is indicated for all approved and off-label uses.
Conclusion
The increased availability and demonstrated efﬁ  cacy and safety 
of recombinant GH have greatly expanded the scope of GH 
use. Virtually all indications and potential uses for GH need 
further study regarding optimal dosing and duration of therapy. 
New ﬁ  ndings regarding the metabolic and anabolic effects of 
GH have prompted application for new indications and have 
increased off-label use of this drug. The new indication in the 
US for ISS prompts further questions about the morbidity of 
shortness, the value of treating short stature medically, and how 
best to deﬁ  ne and measure the ultimate goals of GH therapy. 
Finally, the new interest and potential uses for GH have 
sparked controversy within the pediatric endocrinology com-
munity. It is important that members of this specialty realize 
that differing points of view exist and that there is room for 
tolerance for diverse opinion regarding treatment eligibility. 
Until more research is done, this ﬁ  eld cannot be approached 
as a black and white, right or wrong, scenario.
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